Drospirenone

Drug Profile

Drospirenone

Alternative Names: LF-111

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Leon Farma
  • Class Androstenes; Antiandrogens; Oral contraceptives; Progesterone congeners
  • Mechanism of Action Mineralocorticoid receptor antagonists; Progesterone receptor agonists; Testosterone congener inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Contraception

Most Recent Events

  • 19 Sep 2016 Leon Farma completes a phase III trial in Contraception/Pregnancy prevention (in adolescents) in Finland, Germany and Sweden (PO) (EudraCT2013-005234-37)
  • 01 Aug 2016 Leon Farma completes phase-III clinical trials in Contraception/Pregnancy prevention (In adolescents, In adults) in USA (PO) (NCT02269241)
  • 01 Oct 2014 Phase-III clinical trials in Contraception/Pregnancy prevention (In adolescents, In adults) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top